FENNEC PHARMACEUTICALS INC

FENC is the ticker symbol for Fennec Pharmaceuticals Inc., a commercial-stage biopharmaceutical company. The stock trades on the Nasdaq Capital Market. FENC represents ownership in a company focused on developing and commercializing therapies for cancer patients, particularly to prevent chemotherapy-induced hearing loss in pediatric patients. Investors track FENC as a small-cap specialty pharmaceutical stock.

Recent performance for FENC depends on the latest trading session and market conditions. For the most current price change, percentage move, and volume, please refer to the live quote and performance chart displayed on this page. That data reflects the latest available market information and is more reliable than any static summary.

Trading activity in FENC can vary based on news, market conditions, and investor interest. To gauge how actively FENC shares change hands, review the average daily volume and current volume shown on this page. Those figures provide a clearer picture of liquidity than a general description, since trading volume can shift significantly over time.

Valuation for a commercial-stage biopharma like FENC often involves more than standard earnings multiples, since profitability may be limited or uneven. Investors may review price-to-sales, price-to-book, cash position, and pipeline prospects. For current valuation metrics such as P/E, P/S, or market capitalization, check the latest data displayed on this page rather than relying on outdated figures.

FENC has not historically paid regular cash dividends, as biopharmaceutical companies often retain capital to fund research, development, and commercialization. Dividend policies can change over time, so investors should verify the latest dividend information on this page or in company filings before assuming any payout. For income-focused investors, this is an important consideration when evaluating FENC.

Key risks for FENC include clinical and regulatory uncertainty, reliance on a limited product portfolio, competition from other therapies, reimbursement and pricing pressure, and the need for ongoing capital. As a small-cap biopharma, FENC may also experience volatile trading and dilution risk. Investors should review risk factors in the company's SEC filings for a complete picture.